Comment
doi: 10.1016/S1470-2045(18)30161-X.
Epub 2018 Mar 21.
Is there any interest in a new BRAF-MEK inhibitor combination in melanoma?
Affiliations
- PMID: 29573940
- DOI: 10.1016/S1470-2045(18)30161-X
Item in Clipboard
Comment
Is there any interest in a new BRAF-MEK inhibitor combination in melanoma?
Lancet Oncol.
2018 May.
Erratum in
-
Correction to Lancet Oncol 2018; 19: 580-81.Lancet Oncol. 2018 May;19(5):e229. doi: 10.1016/S1470-2045(18)30285-7. Lancet Oncol. 2018. PMID: 29726387 No abstract available.
No abstract available
Comment on
-
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.Lancet Oncol. 2018 May;19(5):603-615. doi: 10.1016/S1470-2045(18)30142-6. Epub 2018 Mar 21. Lancet Oncol. 2018. PMID: 29573941 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
